Chan Allyson, Tan Robert, Tan Sofia, Kuhn Micheal, Shwaish Natalie, Chinnock Richard, Tran Huyentran, Frandsen Erik
Loma Linda University Children's Hospital, Loma Linda, California, USA.
Pediatr Transplant. 2025 Aug;29(5):e70136. doi: 10.1111/petr.70136.
Cytomegalovirus (CMV) can cause serious morbidity in transplant patients. Lymphocyte depletion by anti-thymocyte globulin (ATG) may persist for 6 months post-induction, and lower absolute lymphocyte counts (ALC) may increase the risk for CMV. We sought to find the relationship between ALC at induction and CMV viremia in the first 6 months post-transplant.
An analysis of transplant recipients within a set period of time with uniformed induction therapy and CMV prophylaxis. ATG was a primary component of induction and ganciclovir or valganciclovir as prevention of CMV infection. The cohort was dichotomized into low ALC (≤ 0.3 × 10 cells/L) and high ALC (> 0.3 × 10 cells/L) based on lowest ALC during the first 14 days and their clinical characteristics analyzed. CMV viremia was defined as PCR value of > 137 IU/mL regardless of symptoms.
A total of 44 patients were included in this study. CMV viremia occurred in 18% (n = 8). Patients were more likely to develop CMV if post-induction ALC was ≤ 0.3 × 10 cells/L (28% vs. 0%, p = 0.029) and remained significant when adjusted for CMV serostatus (p = 0.04). The total ATG dose (7.5 vs. 4.5 mg/kg) was not predictive of CMV (37% vs. 17%, p = 0.3) nor was treatment for rejection (25% vs. 14%, p = 0.5. Rejection occurred in 7% compared to 20% of patients in the low vs. high ALC group (p = 0.4).
In pediatric heart transplant recipients, there is a higher incidence of CMV if ALC ≤ 0.3 × 10 cells/L during induction, regardless of serostatus. Low ALC levels during induction may identify a high-risk group that could benefit from an altered CMV prophylactic regimen.
巨细胞病毒(CMV)可导致移植患者出现严重发病情况。抗胸腺细胞球蛋白(ATG)引起的淋巴细胞减少在诱导治疗后可能持续6个月,较低的绝对淋巴细胞计数(ALC)可能会增加CMV感染风险。我们试图找出诱导期的ALC与移植后前6个月内CMV病毒血症之间的关系。
对在一段固定时间内接受统一诱导治疗和CMV预防的移植受者进行分析。ATG是诱导治疗的主要成分,更昔洛韦或缬更昔洛韦用于预防CMV感染。根据前14天内的最低ALC将队列分为低ALC(≤0.3×10⁹细胞/L)和高ALC(>0.3×10⁹细胞/L)两组,并分析其临床特征。CMV病毒血症定义为PCR值>137 IU/mL,无论有无症状。
本研究共纳入44例患者。18%(n = 8)发生了CMV病毒血症。诱导治疗后ALC≤0.3×10⁹细胞/L的患者更易发生CMV感染(28%对0%,p = 0.029),在根据CMV血清学状态进行调整后仍具有显著性(p = 0.04)。ATG总剂量(7.5对4.5 mg/kg)不能预测CMV感染情况(37%对17%,p = 0.3),排斥反应治疗情况也不能预测(25%对!4%,p = 0.5)。低ALC组与高ALC组的排斥反应发生率分别为7%和20%(p = 0.4)。
在小儿心脏移植受者中,诱导期ALC≤0.3×10⁹细胞/L时,无论血清学状态如何,CMV感染发生率均较高。诱导期低ALC水平可能识别出可从改变的CMV预防方案中获益的高危组。